Interleukin-18-binding protein
Function
Isoform A binds to IL-18 and inhibits its activity. Functions as an inhibitor of the early TH1 cytokine response.
Involvement in disease
Hepatitis, fulminant viral
FVH
An autosomal recessive form of fulminant viral hepatitis, a disease that strikes otherwise healthy individuals during primary infection with common liver-tropic viruses. FVH is characterized by severe liver destruction in the absence of a preexisting liver disorder, leading to encephalopathy within 8 weeks of the onset of the first symptoms.
None
Disease susceptibility may be associated with variants affecting the gene represented in this entry.
Post-translational modifications
N- and O-glycosylated. O-glycosylated with core 1-like and core 2-like glycans. O-glycan heterogeneity at Ser-53: HexHexNAc (major) and Hex2HexNAc2 (minor). N-glycan heterogeneity at Asn-103: Hex5HexNAc4 (minor), dHex1Hex5HexNAc4 (major) and Hex6HexNAc5 (minor); N-glycan at Asn-147: dHex1Hex5HexNAc4.
Tissue Specificity
Strongly expressed in heart, lung, placenta and spleen.
Cellular localization
- Secreted
Alternative names
Interleukin-18-binding protein, IL-18BP, Tadekinig-alfa, IL18BP